> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Priority Review for BMS’ Ide-Cel
- URL: https://www.fdaweb.com/fda-priority-review-for-bms-ide-cel/
- Published: 2020-09-22T12:00:00.000Z
- Updated: 2026-09-14T16:29:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147707

FDA has granted priority review for the BLA submitted by Bristol-Myers Squibb and bluebird bio for idecabtagene vicleucel (ide-cel), an investigational B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy for treating adults with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. The companies say FDA has set 3/27/2021 as the PDUFA goal date for the BLA.

Ide-Cel was already granted breakthrough therapy designation by FDA. It is not approved for any indication anywhere.